CONFERENCE REPORT: 2005 MIRT WORSHOP

Event Name: 2005 Molecular Imaging Radionuclide Therapy (MIRT) Workshop: Translational Applications of Molecular Imaging and Radionuclide Therapy **Date Held**: June 17 – 18, 2005 **Attendance**: 103 **Location**: Intercontinental Toronto Centre Hotel (The Ballroom), Toronto, Canada

This meeting was organized by the Society of Radiopharmaceutical Sciences (SRS) and the Society of Nuclear Medicine Radiopharmaceutical Science Council (RPSC) and Molecular Imaging Task Force. The RPSC has joined with the SRS to present a series of lectures to educate pre-doctoral and post-doctoral radiopharmaceutical scientists in the design of molecular probes. This meeting was supported by a Grant from the U.S. Department of Energy Office of Biological and Environmental Research.

MIRT Organizers/Moderators:

William C. Eckelman, PhD Michael J. Welch, PhD David R. Vera, PhD

| MIRT Educational Faculty | Торіс |
|--|--|
| Yu-Shin Ding, Brookhaven National Labs | New generation of radiotracers |
| Bernd Pichler, University of Tuebingen | Labeling of stem cells |
| David Vera, UC-San Diego | A receptor-binding optical imaging agent for in vivo measurement of receptor biochemistry |
| George Sgouros, Johns Hopkins Medical Institute | Trends in dosimetry for therapy |
| Richard Laforest, Washington University | Comparing five methods for obtaining input functions |
| Hank Kung, University of Pennsylvania | Mass effects in SPECT, PET, and optical imaging |
| Kathleen Schmidt, NIMH | Resolution, sensitivity, and precision with autoradiography and small animal imaging |
| Paul Scheibe | What is to be gained by imaging the same animal before and after treatment? |
| David Mankoff, University of Washington | True tracers: Comparing FDG & glucose with FLT and thymidine |
| Karen Kurdziel, Virginia Commonwealth University | Imaging multi-drug resistance |
| Kate Dadachova, <i>Albert Einstein College of</i> <i>Medicine</i> | NaI symporter-expressing tissues in vivo |
| Rob Mairs, University of Glasgow | Gene manipulation to enhance targeted radionuclide therapy |
| Jorge Carrasquillo, NIH Clinical Center | Radiolabeled antibodies in the clinic: Individualized therapy |
| Wynn Volkert, University of Missouri | Radiolabeled peptides for diagnosis and therapy |
| Ronald Blasberg, Memorial Sloan Kettering Cancer Center | Reporter gene studies with nuclear and optial tracers: The impact of a diagnostic scan on therapy selection |
| David Scheinberg | Unique applications of alpha therapy |